{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:15:36Z","timestamp":1790946936592,"version":"4.1.0"},"reference-count":264,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.gastrohep.2021.07.011","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T20:52:24Z","timestamp":1633726344000},"page":"392-417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["V Conferencia Espa\u00f1ola de Consenso sobre el tratamiento de la infecci\u00f3n por Helicobacter pylori"],"prefix":"10.1016","volume":"45","author":[{"given":"Javier P.","family":"Gisbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Alcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Amador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Bujanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Castro-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fern\u00e1ndez-Salazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emili","family":"Gen\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Lanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo J.","family":"Lucendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga P.","family":"Nyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"P\u00e9rez-Aisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2021.07.011_bib1000","first-page":"777","article-title":"[Helicobacter pylori infection, The Spanish consensus report. The Spanish Consensus Conference Group]","volume":"91","author":"Sainz","year":"1999","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0025-7753(00)71237-1","article-title":"[Treatment for the eradication of Helicobacter pylori, Recommendations of the Spanish Consensus Conference]","volume":"114","author":"Gisbert","year":"2000","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1010","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4321\/S1130-01082005000500007","article-title":"Indications, diagnostic tests and Helicobacter pylori eradication therapy Recommendations by the 2nd Spanish Consensus Conference","volume":"97","author":"Mones","year":"2005","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1157\/13078424","article-title":"[Eradication treatment of Helicobacter pylori, Recommendations of the II Spanish Consensus Conference]","volume":"125","author":"Gisbert","year":"2005","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.gastrohep.2013.01.011","article-title":"[III Spanish Consensus Conference on Helicobacter pylori infection]","volume":"36","author":"Gisbert","year":"2013","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1025","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.gastrohep.2016.05.003","article-title":"[IV Spanish Consensus Conference on Helicobacter pylori infection treatment]","volume":"39","author":"Gisbert","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1030","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1035","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1157\/13117903","article-title":"[How can we find, design, evaluate and use clinical practice guidelines?.]","volume":"31","author":"Gisbert","year":"2008","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1040","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0016-3287(69)80025-X","article-title":"Experimental Study of Group Opinion-Delphi Method","volume":"1","author":"Dalkey","year":"1969","journal-title":"Features"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1155\/2014\/680829","article-title":"Canadian Association of Gastroenterology policy on the application for, and implementation of, clinical practice guidelines","volume":"28","author":"Singh","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1050","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1093\/jac\/dkv155","article-title":"Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection","volume":"70","author":"Lopez-Gongora","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1055","first-page":"2447","article-title":"Systematic review: third-line susceptibilityguided treatment for Helicobacter pylori infection","volume":"70","author":"Puig","year":"2015","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1060","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820968736","article-title":"Empirical or susceptibility-guided treatment for Helicobacter pylori infection?. A comprehensive review","volume":"13","author":"Gisbert","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1065","article-title":"Empirical versus susceptibility-guided treatment of Helicobacter pylori infection: a meta-analysis","author":"Espada","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.gastrohep.2010.10.013","article-title":"[Rescue therapy after Helicobacter pylori eradication failure]","volume":"34","author":"Gisbert","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1075","doi-asserted-by":"crossref","first-page":"e12693","DOI":"10.1111\/hel.12693","article-title":"Helicobacter pylori \u201cTest-and-Treat\u201d strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative","volume":"25","author":"Beresniak","year":"2020","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1080","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto global consensus report on Helicobacter pylori gastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00042737-199701000-00002","article-title":"Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report, The European Helicobacter Pylori Study Group (EHPSG)","volume":"9","author":"Malfertheiner","year":"1997","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1046\/j.1365-2036.2002.01169.x","article-title":"Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report","volume":"16","author":"Malfertheiner","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1095","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/gut.2006.101634","article-title":"Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report","volume":"56","author":"Malfertheiner","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1100","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/gutjnl-2012-302084","article-title":"Management of Helicobacter pylori infection--the Maastricht IV\/Florence Consensus Report","volume":"61","author":"Malfertheiner","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1105","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","article-title":"Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence","volume":"12","author":"Graham","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1110","first-page":"22","article-title":"Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies","author":"Gisbert","year":"2017","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1115","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","article-title":"Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions","volume":"155","author":"Savoldi","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1120","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","article-title":"Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report","volume":"66","author":"Malfertheiner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1125","first-page":"23","article-title":"Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens","author":"Munoz-Gomez","year":"2018","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1130","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2021-324032","article-title":"Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community","author":"Megraud","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1135","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1365-2036.2011.04887.x","article-title":"Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough","volume":"34","author":"Gisbert","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1140","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.gastrohep.2013.02.006","article-title":"[Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]","volume":"36","author":"Molina-Infante","year":"2013","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1145","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1093\/jac\/dkv089","article-title":"First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial","volume":"70","author":"Cuadrado-Lavin","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1150","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1097\/MEG.0000000000000197","article-title":"Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions","volume":"26","author":"Martos","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1155","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.gastrohep.2016.03.002","article-title":"[10-day triple therapy with esomeprazole 40mg\/12h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]","volume":"39","author":"Campillo","year":"2016","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1160","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.medcli.2016.05.017","article-title":"[Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]","volume":"147","author":"Campillo","year":"2016","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1165","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.gastrohep.2017.05.017","article-title":"Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial","volume":"40","author":"Ramas","year":"2017","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1170","doi-asserted-by":"crossref","first-page":"e12630","DOI":"10.1111\/hel.12630","article-title":"As Scientific Committee of the Hp-Eureg on Behalf of the National C Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg)","volume":"24","author":"McNicholl","year":"2019","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1175","first-page":"10","article-title":"European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain","author":"Caldas","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1180","article-title":"Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)","author":"Nyssen","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1185","doi-asserted-by":"crossref","first-page":"e12593","DOI":"10.1111\/hel.12593","article-title":"Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions","volume":"24","author":"McNicholl","year":"2019","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1190","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/apt.16295","article-title":"Review article: potassium-competitive acid blockers for the treatment of acid-related disorders","volume":"53","author":"Abdel-Aziz","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1195","first-page":"1","article-title":"Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: Systematic review and meta-analysis","author":"Shinozaki","year":"2020","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1200","doi-asserted-by":"crossref","first-page":"9781212","DOI":"10.1155\/2019\/9781212","article-title":"Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials","volume":"2019","author":"Lyu","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1205","doi-asserted-by":"crossref","first-page":"e12495","DOI":"10.1111\/hel.12495","article-title":"Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori","volume":"23","author":"Li","year":"2018","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1210","doi-asserted-by":"crossref","first-page":"e12438","DOI":"10.1111\/hel.12438","article-title":"Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?","volume":"22","author":"Dong","year":"2017","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1215","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/apt.14130","article-title":"Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication","volume":"46","author":"Jung","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1220","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/gutjnl-2012-302254","article-title":"Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption","volume":"62","author":"Megraud","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1225","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/hel.12187","article-title":"Helicobacter pylori infection in children antimicrobial resistance and treatment response","volume":"20","author":"Montes","year":"2015","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1230","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000435949","article-title":"Prevalence of primary resistance of Helicobacter pylori to clarithromycin and levofloxacin in Southern Spain","volume":"92","author":"Navarro-Jarabo","year":"2015","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1235","doi-asserted-by":"crossref","first-page":"e12440","DOI":"10.1111\/hel.12440","article-title":"High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross-sectional study in Spain","volume":"22","author":"Macias-Garcia","year":"2017","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1240","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastrohep.2019.05.002","article-title":"Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study","volume":"42","author":"Morilla","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1245","doi-asserted-by":"crossref","first-page":"e12557","DOI":"10.1111\/hel.12557","article-title":"Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies","volume":"24","author":"Cosme","year":"2019","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1250","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","article-title":"Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a Network Meta-Analysis","volume":"161","author":"Rokkas","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1255","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1365-2036.2011.04770.x","article-title":"Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori","volume":"34","author":"Gisbert","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1260","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CEG.S25419","article-title":"Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori","volume":"5","author":"Gisbert","year":"2012","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1265","first-page":"1","article-title":"Eradication of Helicobacter pylori infection with non-bismuth quadruple concomitant therapy","volume":"8","author":"Gisbert","year":"2020"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1270","article-title":"Non-bismuth quadruple concomitant treatment for H. pylori eradication: systematic review and meta-analysis","author":"Espada","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1523-5378.2011.00823.x","article-title":"A new modified concomitant therapy for Helicobacter pylori eradication in Turkey","volume":"16","author":"Toros","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1280","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/hel.12034","article-title":"Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study","volume":"18","author":"Lim","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1285","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/jgh.12983","article-title":"Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial","volume":"30","author":"Heo","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hel.12242","article-title":"Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial","volume":"21","author":"Zhou","year":"2016","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1295","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1523-5378.2012.00947.x","article-title":"Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains","volume":"17","author":"Molina-Infante","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1300","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.gastro.2013.03.050","article-title":"Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance","volume":"145","author":"Molina-Infante","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1305","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/gutjnl-2013-304820","article-title":"Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice","volume":"63","author":"McNicholl","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1310","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/apt.13069","article-title":"Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study","volume":"41","author":"Molina-Infante","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1315","first-page":"A65","article-title":"Non bismuth quadruple \u201cconcomitant\u201d therapies in the eradication of Helicobacter pylori: standard vs. optimized (14 days, high-dose PPI) regimens in clinical practice","volume":"3","author":"McNicholl","year":"2015","journal-title":"United European Gastroenterol Journal"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1320","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hel.12231","article-title":"Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance","volume":"21","author":"Cosme","year":"2016","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1325","doi-asserted-by":"crossref","first-page":"e12529","DOI":"10.1111\/hel.12529","article-title":"Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial","volume":"23","author":"McNicholl","year":"2018","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1330","first-page":"9","article-title":"High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care, An Observational Multicenter Study","author":"Olmedo","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1335","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gutjnl-2020-321372","article-title":"European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients","volume":"70","author":"Nyssen","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1340","article-title":"First-line empirical H. pylori eradication therapy in Europe: Results from 30,000 cases of the European Registry on H. pylori Management (Hp-EuReg)","author":"Nyssen","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1345","doi-asserted-by":"crossref","first-page":"f4587","DOI":"10.1136\/bmj.f4587","article-title":"Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy","volume":"347","author":"Gatta","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1350","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/jgh.12397","article-title":"Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults?","volume":"28","author":"Yoon","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1355","article-title":"Sequential therapy or standard triple therapy for Helicobacter pylori infection: An updated systematic review","author":"Feng","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1360","article-title":"Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial","author":"Liou","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1365","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009034.pub2","article-title":"Sequential versus standard triple first-line therapy for Helicobacter pylori eradication","author":"Nyssen","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1370","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/MCG.0b013e3181c8a1a3","article-title":"Sequential therapy for Helicobacter pylori eradication: a critical review","volume":"44","author":"Gisbert","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1375","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/hel.12240","article-title":"Sequential Therapy for Helicobacter pylori Infection in Treatment-naive Children","volume":"21","author":"Schwarzer","year":"2015","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1380","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/1756283X11432492","article-title":"The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy","volume":"5","author":"Megraud","year":"2012","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1385","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1046\/j.1365-2036.2003.01566.x","article-title":"Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis","volume":"17","author":"Gene","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1390","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/ajg.2009.508","article-title":"Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability","volume":"105","author":"Luther","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1395","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000350719","article-title":"Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection","volume":"88","author":"Venerito","year":"2013","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1400","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/S0140-6736(16)31409-X","article-title":"Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial","volume":"388","author":"Liou","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1405","doi-asserted-by":"crossref","first-page":"e12722","DOI":"10.1111\/hel.12722","article-title":"Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg)","volume":"25","author":"Nyssen","year":"2020","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1410","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(11)60020-2","article-title":"Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial","volume":"377","author":"Malfertheiner","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1415","doi-asserted-by":"crossref","first-page":"e12570","DOI":"10.1111\/hel.12570","article-title":"Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori","volume":"24","author":"Nyssen","year":"2019","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1420","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.gtc.2015.05.003","article-title":"How to effectively use bismuth quadruple therapy: The good, the bad, and the ugly","volume":"44","author":"Graham","year":"2015","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1425","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/gutjnl-2015-309900","article-title":"Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy","volume":"64","author":"Zhang","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1430","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.14309\/ajg.0000000000001246","article-title":"Adverse event profile during the treatment of Helicobacter pylori: A real-world experience of 22,000 patients from the European Registry on H. pylori Management (Hp-EuReg)","volume":"116","author":"Nyssen","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1435","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/2050640620972615","article-title":"European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice","volume":"9","author":"Nyssen","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1440","doi-asserted-by":"crossref","first-page":"552","DOI":"10.17235\/reed.2017.4809\/2016","article-title":"A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naive and previously treated patients","volume":"109","author":"Gomez Rodriguez","year":"2017","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1445","first-page":"483","article-title":"Retrospective analysis of the use of quadruple therapy with bismuth (Pylera((R))) in real-life clinical practice in Spain","volume":"41","author":"Agudo-Fernandez","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1450","first-page":"145","article-title":"Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice","volume":"41","author":"Perez-Arellano","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1455","doi-asserted-by":"crossref","first-page":"e12546","DOI":"10.1111\/hel.12546","article-title":"Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial","volume":"24","author":"Macias-Garcia","year":"2019","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1460","doi-asserted-by":"crossref","first-page":"467","DOI":"10.17235\/reed.2019.5950\/2018","article-title":"Compliance, adverse effects and effectiveness of first line bismuth-containing quadruple treatment (Pylera(R)) to eradicate Helicobacter pylori infection in 200 patients","volume":"111","author":"Castro Fernandez","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1465","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.gastrohep.2019.12.002","article-title":"Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy","volume":"43","author":"Alcedo","year":"2020","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1470","doi-asserted-by":"crossref","DOI":"10.1177\/2050640620972615","article-title":"Experience with single capsule bismuth quadruple therapy in 5,000 patients from the European Registry on H. pylori Management (Hp-EuReg)","author":"Nyssen","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1475","doi-asserted-by":"crossref","first-page":"104661","DOI":"10.1016\/j.micpath.2020.104661","article-title":"Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis","volume":"152","author":"Guo","year":"2021","journal-title":"Microb Pathog"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1480","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cgh.2019.03.048","article-title":"Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients","volume":"18","author":"McNicholl","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1485","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1523-5378.1998.08019.x","article-title":"Amoxicillin\/metronidazole\/omeprazole\/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication","volume":"3","author":"Treiber","year":"1998","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1490","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1007\/s005350050150","article-title":"A new quadruple therapy for the eradication of Helicobacter pylori Effect of pretreatment with omeprazole on the cure rate","volume":"33","author":"Okada","year":"1998","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1495","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archinte.162.2.153","article-title":"Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study)","volume":"162","author":"Treiber","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1500","first-page":"135","article-title":"Effectiveness of 5-day and 7-day quadruple \u201cconcomitant\u201d therapy regimen for Helicobacter pylori infection in Korea","volume":"16","author":"Kwon","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1505","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1523-5378.2012.00953.x","article-title":"Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand","volume":"17","author":"Kongchayanun","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1510","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1099\/jmm.0.072322-0","article-title":"Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study","volume":"63","author":"De Francesco","year":"2014","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1515","doi-asserted-by":"crossref","first-page":"e12694","DOI":"10.1111\/hel.12694","article-title":"Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study","volume":"25","author":"Romano","year":"2020","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1520","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2036.2004.02248.x","article-title":"Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies","volume":"20","author":"Fischbach","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1525","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1523-5378.2011.00857.x","article-title":"Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days","volume":"16","author":"Dore","year":"2011","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1530","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMra1807761","article-title":"Penicillin Allergy","volume":"381","author":"Castells","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1535","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1046\/j.1365-2036.2000.00844.x","article-title":"Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori","volume":"14","author":"Gisbert","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1540","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1365-2036.2005.02687.x","article-title":"Helicobacter pylori first-line treatment and rescue options in patients allergic to penicillin","volume":"22","author":"Gisbert","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1545","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.dld.2009.06.007","article-title":"Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin","volume":"42","author":"Gisbert","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1550","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0025-7753(01)71738-1","article-title":"[Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review]","volume":"116","author":"Gisbert","year":"2001","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1555","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s10620-005-2549-1","article-title":"High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin","volume":"50","author":"Rodriguez-Torres","year":"2005","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1560","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1440-1746.2006.04171.x","article-title":"Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection","volume":"21","author":"Matsushima","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1565","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2036.2007.03386.x","article-title":"Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori","volume":"26","author":"Fischbach","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1570","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/s10620-014-3365-2","article-title":"Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy","volume":"60","author":"Gisbert","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1575","doi-asserted-by":"crossref","first-page":"e12686","DOI":"10.1111\/hel.12686","article-title":"Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)","volume":"25","author":"Nyssen","year":"2020","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1580","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.cgh.2013.01.008","article-title":"Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study","volume":"11","author":"Liang","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1585","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1053\/j.gastro.2020.05.059","article-title":"AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders","volume":"159","author":"Su","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1590","first-page":"217","article-title":"Probiotics and Helicobacter pylori infection","volume":"14","author":"Praitano","year":"2012","journal-title":"Medicina Universitaria"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1595","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/MEG.0b013e32830d0eff","article-title":"Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials","volume":"21","author":"Sachdeva","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1600","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1365-2036.2010.04457.x","article-title":"Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment","volume":"32","author":"Szajewska","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1605","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MCG.0b013e318266f6cf","article-title":"Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy","volume":"47","author":"Wang","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1610","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4321\/S1130-01082013000800002","article-title":"Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis","volume":"105","author":"Zheng","year":"2013","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1615","doi-asserted-by":"crossref","first-page":"18013","DOI":"10.3748\/wjg.v20.i47.18013","article-title":"Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy","volume":"20","author":"Zhu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1620","doi-asserted-by":"crossref","first-page":"e111030","DOI":"10.1371\/journal.pone.0111030","article-title":"The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis","volume":"9","author":"Dang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1625","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00431-013-2220-3","article-title":"Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children","volume":"173","author":"Li","year":"2014","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1630","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.3748\/wjg.v21.i14.4345","article-title":"Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis","volume":"21","author":"Zhang","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1635","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3892\/etm.2015.2174","article-title":"Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis","volume":"9","author":"Lv","year":"2015","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1640","first-page":"6530","article-title":"Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials","volume":"8","author":"Gong","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1645","doi-asserted-by":"crossref","first-page":"23522","DOI":"10.1038\/srep23522","article-title":"Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis","volume":"6","author":"Lu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1650","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1177\/2050640615617358","article-title":"Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events","volume":"4","author":"McFarland","year":"2016","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1655","doi-asserted-by":"crossref","first-page":"e0163743","DOI":"10.1371\/journal.pone.0163743","article-title":"Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Lu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1660","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.clinre.2017.04.004","article-title":"Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis","volume":"41","author":"Wang","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1665","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00228-017-2291-6","article-title":"Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis","volume":"73","author":"Feng","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1670","doi-asserted-by":"crossref","first-page":"96409","DOI":"10.18632\/oncotarget.21633","article-title":"Probiotics in 14-day triple therapy for Asian pediatric patients with Helicobacter pylori infection: a network meta-analysis","volume":"8","author":"Wen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1675","doi-asserted-by":"crossref","first-page":"e15180","DOI":"10.1097\/MD.0000000000015180","article-title":"Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis","volume":"98","author":"Shi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1680","doi-asserted-by":"crossref","first-page":"3409820","DOI":"10.1155\/2019\/3409820","article-title":"Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus(R)) and a Proton-Pump Inhibitor","volume":"2019","author":"Dore","year":"2019","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1685","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.3748\/wjg.v18.i43.6250","article-title":"Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation","volume":"18","author":"Efrati","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1690","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1523-5378.2012.00945.x","article-title":"Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate","volume":"17","author":"Manfredi","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1695","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-230X-13-56","article-title":"Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study","volume":"13","author":"Navarro-Rodriguez","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1700","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/hel.12047","article-title":"The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study","volume":"18","author":"Shavakhi","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1705","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1097\/MD.0000000000000685","article-title":"Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial","volume":"94","author":"Hauser","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1710","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4321\/S1130-01082013000800001","article-title":"Probiotics for Helicobacter pylori eradication therapy: not ready for prime time","volume":"105","author":"Molina-Infante","year":"2013","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1715","doi-asserted-by":"crossref","first-page":"10338","DOI":"10.3748\/wjg.v20.i30.10338","article-title":"Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance","volume":"20","author":"Molina-Infante","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1720","doi-asserted-by":"crossref","DOI":"10.17235\/reed.2021.7931\/2021","article-title":"Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori","author":"Moreno Marquez","year":"2021","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1725","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.31557\/APJCP.2019.20.9.2859","article-title":"High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study","volume":"20","author":"Poonyam","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1730","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1517\/14656566.2013.782286","article-title":"A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication)","volume":"14","author":"Marin","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1735","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5009\/gnl20288","article-title":"Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020","volume":"15","author":"Jung","year":"2021","journal-title":"Gut Liver"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1740","article-title":"Empirical second-line treatments in Europe: Results from the European Registry on H. pylori Management (Hp-EuReg)","author":"Nyssen","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1745","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.3390\/molecules25215084","article-title":"Optimization strategies aimed to increase the efficacy of helicobacter pylori eradication therapies with quinolones","volume":"25","author":"Gisbert","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1750","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.2006.02737.x","article-title":"Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure","volume":"23","author":"Gisbert","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1755","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1572-0241.2006.00637.x","article-title":"Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis","volume":"101","author":"Saad","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1760","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00508-010-1404-3","article-title":"Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis","volume":"122","author":"Li","year":"2010","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1765","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.3748\/wjg.v18.i40.5669","article-title":"Levofloxacin\/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line","volume":"18","author":"Di Caro","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1770","first-page":"368","article-title":"[Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of Helicobacter pylori as the rescue therapy: a meta analysis]","volume":"56","author":"Zhang","year":"2017","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1775","doi-asserted-by":"crossref","first-page":"e12488","DOI":"10.1111\/hel.12488","article-title":"Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori","volume":"23","author":"Munoz","year":"2018","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1780","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/jgh.14462","article-title":"Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication","volume":"34","author":"Yeo","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1785","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MCG.0b013e318254ebdd","article-title":"Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients","volume":"47","author":"Gisbert","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1790","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s40265-017-0730-4","article-title":"Efficacy and safety of quinolone-containing rescue therapies after the failure of non-bismuth quadruple treatments for Helicobacter pylori eradication: Systematic review and meta-analysis","volume":"77","author":"Marin","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1795","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/hel.12062","article-title":"Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area","volume":"18","author":"Georgopoulos","year":"2013","journal-title":"Helicobacter"},{"issue":"5 suppl.1","key":"10.1016\/j.gastrohep.2021.07.011_bib1800","article-title":"Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple \u201csequential\u201d or \u201cconcomitant\u201d treatment to eradicate H. pylori infection","volume":"146","author":"Gisbert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1805","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.dld.2007.06.016","article-title":"Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance","volume":"39","author":"Perna","year":"2007","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1810","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.dld.2009.12.007","article-title":"Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice","volume":"42","author":"Pontone","year":"2010","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1815","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2217\/14750708.3.2.251","article-title":"Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study","volume":"3","author":"Zullo","year":"2006","journal-title":"Therapy"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1820","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.clinre.2013.04.003","article-title":"Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study","volume":"37","author":"Zullo","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1825","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.dld.2008.09.013","article-title":"Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication","volume":"41","author":"Di Caro","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1830","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1523-5378.2012.00960.x","article-title":"The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin\/amoxicillin\/proton-pump inhibitor treatment--a pilot study","volume":"17","author":"Chuah","year":"2012","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1835","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nrgastro.2010.131","article-title":"Bismuth improves PPI-based triple therapy for H. pylori eradication","volume":"7","author":"Malfertheiner","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1840","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/hel.12052","article-title":"Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy","volume":"18","author":"Liao","year":"2013","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1845","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1159\/000484930","article-title":"Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen","volume":"26","author":"Kahramanoglu Aksoy","year":"2017","journal-title":"Med Princ Pract"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1850","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3109\/00365521.2015.1037345","article-title":"Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial","volume":"50","author":"Cao","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1855","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00508-007-0807-2","article-title":"High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial","volume":"119","author":"Bago","year":"2007","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1860","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s10620-017-4564-4","article-title":"Randomized clinical trial: Esomeprazole, bismuth, levofloxacin, and amoxicillin or cefuroxime as first-line eradication regimens for Helicobacter pylori infection","volume":"62","author":"Fu","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1865","doi-asserted-by":"crossref","first-page":"9045","DOI":"10.1038\/s41598-018-27482-2","article-title":"Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial","volume":"8","author":"Gan","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1870","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.3748\/wjg.v16.i34.4357","article-title":"Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication","volume":"16","author":"Gao","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1875","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/apt.13128","article-title":"Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1880","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2362.2008.01951.x","article-title":"Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures","volume":"38","author":"Hsu","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1885","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.dld.2016.01.002","article-title":"Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy","volume":"48","author":"Song","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1890","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1365-2036.2007.03452.x","article-title":"Clinical trial: levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection","volume":"26","author":"Yee","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1895","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gutjnl-2013-306120","article-title":"Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial","volume":"63","author":"Liu","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1900","article-title":"Efficacy of the 14-Day Quadruple Regimen (Proton Pump Inhibitor, Bismuth Tetracycline and Metronidazole) as a Rescue Therapy After Failure With the 10-Days Sequential Therapy for Eradication of Helicobacter pylori","volume":"138","author":"Kim","year":"2010","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1905","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/apt.13177","article-title":"Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance","volume":"41","author":"Graham","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1910","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkr410","article-title":"Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain","volume":"67","author":"Cuadrado-Lavin","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1915","doi-asserted-by":"crossref","first-page":"e13150","DOI":"10.1111\/eci.13150","article-title":"Helicobacter pylori pathogenicity and primary antimicrobial resistance in Northern Spain","volume":"49","author":"Fernandez-Reyes","year":"2019","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1920","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4318\/tjg.2010.0041","article-title":"Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia","volume":"21","author":"Ercin","year":"2010","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1925","doi-asserted-by":"crossref","first-page":"348","DOI":"10.5455\/medarh.2013.67.348-350","article-title":"The efficacy of levofloxacin-based triple therapy for first-line helicobacter pylori eradication","volume":"67","author":"Telaku","year":"2013","journal-title":"Med Arch"},{"issue":"1S","key":"10.1016\/j.gastrohep.2021.07.011_bib1930","first-page":"A5","article-title":"The efficacy of second-line anti-Helicobacter pylori eradication using 10-day and 14-day levofloxacin-containing triple therapy","volume":"1","author":"Tai","year":"2013","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1935","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1523-5378.2007.00507.x","article-title":"Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy","volume":"12","author":"Cheng","year":"2007","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1940","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.gtc.2010.08.007","article-title":"Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection","volume":"39","author":"Furuta","year":"2010","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1945","first-page":"131","article-title":"Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice","volume":"19","author":"Zullo","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1950","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.gastrohep.2019.03.008","article-title":"Warnings on the safety of quinolones: Should Helicobacter pylori treatment prescriptions be modified?","volume":"42","author":"McNicholl","year":"2019","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1955","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1960","first-page":"22","article-title":"Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin","author":"Ono","year":"2017","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1965","doi-asserted-by":"crossref","first-page":"571","DOI":"10.2169\/internalmedicine.53.1677","article-title":"Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin","volume":"53","author":"Furuta","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1970","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1177\/2050640616688995","article-title":"Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients","volume":"5","author":"Mori","year":"2017","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1975","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10620-013-2900-x","article-title":"Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection","volume":"59","author":"Gisbert","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1980","doi-asserted-by":"crossref","first-page":"e12423","DOI":"10.1111\/hel.12423","article-title":"Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera((R))) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study","volume":"22","author":"Rodriguez de Santiago","year":"2017","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1985","doi-asserted-by":"crossref","first-page":"e2750","DOI":"10.1097\/MD.0000000000002750","article-title":"Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1990","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1523-5378.2005.00324.x","article-title":"Helicobacter pylori \u201crescue\u201d therapy after failure of two eradication treatments","volume":"10","author":"Gisbert","year":"2005","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib1995","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1572-0241.2006.00457.x","article-title":"Third-line rescue therapy with levofloxacin after two H. pylori treatment failures","volume":"101","author":"Gisbert","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2000","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1111\/j.1365-2036.2012.05117.x","article-title":"Letter: third-line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2036.2005.02522.x","article-title":"A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses","volume":"22","author":"Gatta","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2010","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/j.1365-2036.2006.03149.x","article-title":"Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures","volume":"24","author":"Gisbert","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2015","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ajg.2008.87","article-title":"Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen","volume":"104","author":"Rokkas","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/ygh2.372","article-title":"Empirical Helicobacter pylori rescue therapy: an 18-year single-centre study of 1200 patients","volume":"1","author":"Burgos-Santamaria","year":"2019","journal-title":"GastroHep"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2025","first-page":"8S","article-title":"European registry on H. pylori management (Hp-EuReg): analysis of 1,782 empirical rescue therapies on third and subsequent lines","volume":"8","author":"Burgos-Santamaria","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2036.2011.04937.x","article-title":"Review article: rifabutin in the treatment of refractory Helicobacter pylori infection","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/pathogens10010015","article-title":"Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review","volume":"10","author":"Gisbert","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2040","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2036.2007.03573.x","article-title":"Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients","volume":"27","author":"Gisbert","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004836-200010000-00007","article-title":"Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience","volume":"31","author":"Bock","year":"2000","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1523-5378.2007.00588.x","article-title":"One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin","volume":"13","author":"Miehlke","year":"2008","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2055","first-page":"303","article-title":"Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection","volume":"24","author":"Van Zanten","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2060","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1365-2036.2012.05053.x","article-title":"Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures","volume":"35","author":"Gisbert","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejim.2020.06.029","article-title":"Rifabutin-based triple therapy or bismuth-based quadruple regimen as rescue therapies for Helicobacter pylori infection","volume":"81","author":"Saracino","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2070","doi-asserted-by":"crossref","first-page":"e12719","DOI":"10.1111\/hel.12719","article-title":"Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study","volume":"25","author":"Hirata","year":"2020","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2075","article-title":"Experience with rifabutin-containing therapy in 426 patients from the European Registry on H. pylori Management (Hp-EuReg)","author":"Nyssen","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2080","doi-asserted-by":"crossref","first-page":"367","DOI":"10.15403\/jgld.2014.1121.234.qrth","article-title":"Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens","volume":"23","author":"Ierardi","year":"2014","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2085","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/apt.12089","article-title":"Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations","volume":"36","author":"Tay","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2090","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/hel.12296","article-title":"Rifabutin containing triple therapy and rifabutin with bismuth containing quadruple therapy for third-line treatment of Helicobacter pylori infection: Two pilot studies","volume":"21","author":"Ciccaglione","year":"2016","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2095","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820937115","article-title":"High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis","volume":"13","author":"Zhu","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2100","doi-asserted-by":"crossref","first-page":"e12692","DOI":"10.1111\/hel.12692","article-title":"PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis","volume":"25","author":"Gao","year":"2020","journal-title":"Helicobacter"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2105","first-page":"693","article-title":"[Helicobacter pylori and duodenal ulcer: a causal relation or mere association?.]","volume":"197","author":"Gisbert","year":"1997","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2110","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2036.2005.02418.x","article-title":"Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer?","volume":"21","author":"Gisbert","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2115","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1046\/j.1365-2036.2002.01260.x","article-title":"Duodenal ulcer healing with 1-week eradication triple therapy followed, or not, by anti-secretory treatment: a multicentre double-blind placebo-controlled trial","volume":"16","author":"Colin","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2120","first-page":"1731","article-title":"One-week low-dose triple therapy without anti-acid treatment has sufficient efficacy on Helicobacter pylori eradication and ulcer healing","volume":"50","author":"Hsu","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2125","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2036.1997.80252000.x","article-title":"One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers","volume":"11","author":"Labenz","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S1590-8658(02)00006-3","article-title":"Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial","volume":"35","author":"Marzio","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2135","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2036.2001.01020.x","article-title":"Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer?","volume":"15","author":"Tepes","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2140","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/00042737-200112000-00009","article-title":"One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease","volume":"13","author":"Tulassay","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2145","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10620-006-9522-5","article-title":"One week of esomeprazole triple therapy vs 1 week of omeprazole triple therapy plus 3 weeks of omeprazole for duodenal ulcer healding in Helicobacter pylori-positive patients","volume":"52","author":"Subei","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3164\/jcbn.12-15","article-title":"Strategies for peptic ulcer healing after 1 week proton pump inhibitor-based triple Helicobacter pylori eradication therapy in Japanese patients: differences of gastric ulcers and duodenal ulcers","volume":"51","author":"Takeuchi","year":"2012","journal-title":"J Clin Biochem Nutr"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2155","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1572-0241.1998.00333.x","article-title":"The impact of Helicobacter pylori eradication on peptic ulcer healing","volume":"93","author":"Treiber","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2160","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1046\/j.1365-2036.2001.01109.x","article-title":"A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer","volume":"15","author":"Leodolter","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2165","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1046\/j.1365-2036.2000.00803.x","article-title":"Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage","volume":"14","author":"Lai","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2036.2003.01402.x","article-title":"Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori?. A randomized, controlled, prospective study","volume":"17","author":"Higuchi","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/MEG.0b013e3282f427ac","article-title":"Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients","volume":"20","author":"Tulassay","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/00365521.2003.11800649","article-title":"Helicobacter pylori and bleeding peptic ulcer: what is the prevalence of the infection in patients with this complication?","volume":"38","author":"Gisbert","year":"2003","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2185","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004062.pub2","article-title":"H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer","author":"Gisbert","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2190","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.2004.01898.x","article-title":"Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer","volume":"19","author":"Gisbert","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2195","first-page":"47","article-title":"[Absence of bleeding recurrence of peptic ulcer after long term follow-up of successful eradication of Helicobacter pylori]","volume":"29","author":"Amendola","year":"1999","journal-title":"Acta Gastroenterol Latinoam"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2200","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1111\/j.1572-0241.2003.07682.x","article-title":"Eradication of Helicobacter pylori improves the healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer","volume":"98","author":"Arkkila","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2205","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1365-2036.2001.00992.x","article-title":"Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection","volume":"15","author":"Capurso","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2210","first-page":"161","article-title":"[Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence]","volume":"112","author":"Gisbert","year":"1999","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2215","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3109\/00365529309098288","article-title":"Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease","volume":"28","author":"Graham","year":"1993","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2220","first-page":"139","article-title":"The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer","volume":"29","author":"Horvat","year":"2005","journal-title":"Coll Antropol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0016-5107(95)70267-9","article-title":"Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage","volume":"41","author":"Jaspersen","year":"1995","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2230","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF02347506","article-title":"Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study","volume":"30","author":"Jaspersen","year":"1995","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2235","first-page":"183","article-title":"Comparative amoxicillin Azithromycin treatment of Helicobacter pylori positive patients with bleeding duodenal ulcer","volume":"47","author":"Krizman","year":"1997","journal-title":"Acta Pharmaceutica"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2240","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000201117","article-title":"Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse","volume":"55","author":"Labenz","year":"1994","journal-title":"Digestion"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2245","first-page":"2225","article-title":"Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage--a long-term randomized, controlled study","volume":"95","author":"Lai","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2250","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/archinte.163.17.2020","article-title":"Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study","volume":"163","author":"Liu","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2255","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1572-0241.1998.00278.x","article-title":"Eradication of Helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study","volume":"93","author":"Macri","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2260","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004836-200103000-00008","article-title":"The effect of the eradication of Helicobacter pylori infection on hemorrhage because of duodenal ulcer","volume":"32","author":"Pellicano","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2265","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0016-5107(97)70114-7","article-title":"Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer bleeding","volume":"46","author":"Riemann","year":"1997","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0016-5107(95)70266-0","article-title":"Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease","volume":"41","author":"Rokkas","year":"1995","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2275","first-page":"1549","article-title":"Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients","volume":"91","author":"Santander","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2280","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1023\/A:1018816729449","article-title":"One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding","volume":"42","author":"Sung","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2285","first-page":"59","article-title":"Eradication of Helicobacter pylori reduces the possibility of rebleeding in duodenal ulcer disease","volume":"21","author":"Vcev","year":"1996","journal-title":"Acta Fam Med Flum"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2290","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00042737-200012070-00003","article-title":"Helicobacter pylori eradication prevents recurrence from peptic ulcer haemorrhage","volume":"12","author":"Vergara","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2295","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ajg.2012.132","article-title":"Long-term follow-up of 1,000 patients cured of Helicobacter pylori infection following an episode of peptic ulcer bleeding","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2300","doi-asserted-by":"crossref","first-page":"346","DOI":"10.5009\/gnl13451","article-title":"Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients","volume":"9","author":"Chang","year":"2015","journal-title":"Gut Liver"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2305","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.3748\/wjg.v21.i8.2497","article-title":"Optimal initiation of Helicobacter pylori eradication in patients with peptic ulcer bleeding","volume":"21","author":"Yoon","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2310","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cgh.2020.03.071","article-title":"Delay in Retreatment of Helicobacter pylori Infection Increases Risk of Upper Gastrointestinal Bleeding","volume":"19","author":"Guo","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2021.07.011_bib2315","first-page":"143","article-title":"Terapia erradicadora cu\u00e1druple con bismuto en c\u00e1psula \u00fanica (Pylera\u00ae): \u00bf3 \u00f3 4 veces al d\u00eda? Suban\u00e1lisis de los datos espa\u00f1oles del Registro Europeo de H. pylori (Hp-EuReg)","volume":"44","author":"P\u00e9rez-A\u00edsa","year":"2021","journal-title":"Gastroenterol Hepatol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570521002296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570521002296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:45:58Z","timestamp":1759322758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570521002296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":264,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0210570521002296"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2021.07.011","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"V Conferencia Espa\u00f1ola de Consenso sobre el tratamiento de la infecci\u00f3n por Helicobacter pylori","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2021.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}